PFSA (profusa.com) צמיחת רווח נקי למניה השנה

The development of subcutaneous sensors in the US relies on DARPA grants, which shields Profusa Inc (PFSA) from external trade shocks. Innovative biosensors enable the tracking of metabolites for six months without tissue scarring. Collaboration with defense and medical entities is expanding the implementation of monitoring systems. The annual growth trajectory of earnings per share visualizes the market cycle, while the value of 0.00 reflects the metric balance.

For Profusa Inc (PFSA), which develops biosensor technologies through clinical alliances, the annual earnings per share (EPS) calculation reflects the efficiency of monetizing medtech patents. This metric computes the percentage deviation of the current EPS from the value of the same period last year. By analyzing the year-over-year EPS growth trend on GURU.Markets, an investor can see the actual speed of business scaling. However, sharp spikes may mask debt burdens. Stable growth confirms the resilience of the continuous health monitoring model.